PMA device
GORE® VIABAHN® FORTEGRA Venous Stent
W. L. Gore & Associates, Inc. · Stent, Vena Cava (QTL, Class III) · First FDA decision Dec 19, 2025, newest Apr 7, 2026Pulmonary embolism and deep vein thrombosis
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
Breakthrough-designated
Device trials
3
Naming "GORE VIABAHN FORTEGRA"
MAUDE reports
0
Brand "GORE VIABAHN FORTEGRA", since 2015
PubMed studies
0
Mentioning "GORE VIABAHN FORTEGRA"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing GORE® VIABAHN® FORTEGRA Venous Stent
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
- GORE® VIABAHN® FORTEGRA Venous StentPMA supplement
P250017-S001 · Decided Apr 7, 2026 · 76 days after receipt · Normal 180 Day Track No User Fee
Device type: Stent, vena cava (QTL) · Cardiology
- GORE® VIABAHN® FORTEGRA Venous StentBreakthroughPMA
P250017 · Decided Dec 19, 2025 · 182 days after receipt
Device type: Stent, vena cava (QTL) · Cardiology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Percutaneous Transluminal Angioplasty (PTA) of the Carotid Artery Concurrent with StentingNational analysisReview closedCAG-00085R8Updated Sep 21, 2026
- Percutaneous Transluminal Angioplasty (PTA) of the Carotid Artery Concurrent with StentingNational analysisReview closedCAG-00085R7Updated Sep 21, 2026
- Percutaneous Transluminal Angioplasty (PTA) of the Carotid Artery Concurrent with StentingNational analysisReview closedCAG-00085R6Updated Sep 21, 2026
- Percutaneous Transluminal Angioplasty (PTA) of the Carotid Artery Concurrent with StentingNational analysisReview closedCAG-00085R3Updated Sep 21, 2026
- Percutaneous Transluminal Angioplasty (PTA) and Stenting of the Renal ArteriesNational analysisReview closedCAG-00085R4Updated Sep 21, 2026
- Intracranial Stenting and AngioplastyNational analysisReview closedCAG-00085R5Updated Sep 18, 2026
- Intracranial Stenting and AngioplastyNational analysisReview closedCAG-00085R2Updated Sep 18, 2026
- Carotid Artery Stenting in Post-Approval StudiesNational analysisReview closedCAG-00259NUpdated Sep 17, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "GORE VIABAHN FORTEGRA", any status and sponsor, newest update first.
W.L.Gore & AssociatesNot on our public-company list
NCT07538609 · 150 participants (planned) · Start Aug 25, 2026 · Primary completion May 2029
Device: GORE® VIABAHN® FORTEGRA Venous Stent · For: Venous Thromboses; Venous Disease; Venous Leg Ulcer and 5 more
Sites: Darien, Connecticut; Washington D.C., District of Columbia; Dallas, Texas · 4 sites in all
- The GORE® VIABAHN® FORTEGRA Venous Stent IVC StudyActive, not recruiting
W.L.Gore & AssociatesNot on our public-company list
NCT05409976 · 136 participants · Start Oct 25, 2022 · Primary completion May 9, 2026
Device: GORE® VIAFORT Vascular Stent · For: Venous Thromboses; Venous Disease; Venous Leg Ulcer and 7 more
Sites: Stanford, California; Washington D.C., District of Columbia; Chicago, Illinois · 17 sites in all
- The GORE® VIABAHN® FORTEGRA Venous Stent Iliofemoral StudyActive, not recruiting
W.L.Gore & AssociatesNot on our public-company list
NCT05489588 · 165 participants (planned) · Start Mar 2, 2023 · Primary completion Aug 2027
Device: GORE® VIAFORT Vascular Stent · For: Venous Thromboses; Venous Disease; Venous Leg Ulcer and 7 more
Sites: Stanford, California; Darien, Connecticut; New Haven, Connecticut · 24 sites in all
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "GORE VIABAHN FORTEGRA", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code QTL
8 reports: 1 malfunction, 7 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "GORE VIABAHN FORTEGRA"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.